Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
Company profile
Ticker
CMND
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Latest filings (excl ownership)
6-K
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
17 Apr 24
6-K
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
10 Apr 24
6-K
Clearmind Medicine CEO Issues Letter to Shareholders
9 Apr 24
20-F/A
2023 FY
Annual report (foreign) (amended)
27 Mar 24
6-K
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
27 Mar 24
EFFECT
Notice of effectiveness
25 Mar 24
POS AM
Prospectus update (post-effective amendment)
20 Mar 24
6-K
Condensed Interim Consolidated Financial Statements
18 Mar 24
20-F/A
2023 FY
Annual report (foreign) (amended)
18 Mar 24
6-K
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
13 Mar 24
Latest ownership filings
Financial summary
Quarter (USD) | Oct 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Annual (USD) | Oct 22 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Institutional ownership, Q2 2023
19.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 8 |
Opened positions | 6 |
Closed positions | 1 |
Increased positions | 0 |
Reduced positions | 2 |
13F shares | Current |
---|---|
Total value | 107.58 mm |
Total shares | 630.05 k |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Intracoastal Capital | 384.62 k | $148.00 k |
AdvisorShares Investments | 123.26 k | $57.94 mm |
Geode Capital Management | 51.52 k | $24.22 mm |
Citadel Advisors | 37.12 k | $17.45 mm |
HRT Financial | 17.09 k | $8.00 k |
Two Sigma Securities | 12.35 k | $5.87 mm |
Tower Research Capital | 4.08 k | $1.94 mm |
O'Dell | 18.00 | $9.00 k |
Proequities | 0.00 | $0.00 |
News
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
17 Apr 24
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
17 Apr 24
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
30 Mar 24
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
29 Mar 24
SciSparc- Clearmind Collaboration Evolves With New International Patent Application For Preventing And Treating Depression
27 Mar 24
Press releases
Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders
17 Apr 24
Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders
10 Apr 24
Clearmind Medicine CEO Issues Letter to Shareholders
9 Apr 24
Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression
27 Mar 24
SciSparc- Clearmind Collaboration Evolves with New International Patent Application for Preventing and Treating Depression
27 Mar 24